A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease

The most common treatment for patients with sickle cell disease (SCD) is the chemotherapeutic hydroxyurea, a therapy with leiotropic effects, including increasing fetal hemoglobin (HbF) in red blood cells and reducing adhesion of white blood cells to the vascular endothelium. Hydroxyurea has been pr...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Haematologica (Roma) 2020-03, Vol.105 (3), p.623-631
Hauptverfasser:	McArthur, James G., Svenstrup, Niels, Chen, Chunsheng, Fricot, Aurelie, Carvalho, Caroline, Nguyen, Julia, Phong Nguyen, Parachikova, Anna, Abdulla, Fuad, Vercellotti, Gregory M., Hermine, Olivier, Edwards, Dave, Ribeil, Jean-Antoine, Belcher, John D., Maciel, Thiago T.
Format:	Artikel
Sprache:	eng
Schlagworte:	Anemia, Sickle Cell - drug therapy Animals Fetal Hemoglobin Hematology Humans Hydroxyurea - pharmacology K562 Cells Life Sciences & Biomedicine Mice Phosphodiesterase Inhibitors - therapeutic use Phosphoric Diester Hydrolases Science & Technology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!